Treatment of metabolic syndrome slows progression of diabetic nephropathy

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 6, 2011, Pages 483-489

  Duran Perez, Edgar G ^a   Almeda Valdes, Paloma ^a   Cuevas Ramos, Daniel ^a   Campos Barrera, Eugenia ^a   Muñoz Hernandez, Liliana ^a   Gomez Perez, Francisco J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE CONTROL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, THEORETICAL; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 82555195125     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2011.0056     Document Type: Article

References (26)

1. The 2009 USRD Healthy people 2010. Annual Data Report (ADR) Atlas. Available at: www.usrds.org/atlas.htm/. Accessed May 1, 2010.
2. Instituto Nacional de Estadística y Geografía México. Mortalidad General, estadísticas de mortalidad. Available at: http:// www.inegi.org.mx/est/contenidos/ espanol/proyectos/con inuas/vitales/BD/tabulados/ConsultaMortalidad.asp/. Accessed January 1, 2008.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
4. Balkau B, Charles MA. Comment on the provisional report from WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-443.
5. Bianchi C, Penno G, Daniele G et al. The metabolic syndrome is related to albuminuria in type 2 diabetes. Diabet Med 2008;25:1412-1418.
6. Hanai K, Bobazono T, Iwamoto Y. Renal manifestations of metabolic syndrome in type 2 diabetes. Diabetes Res Clin Pract 2008;79:318-324.
7. De Cosmo S, Trevisan R, Minenna A et al. Insulin resistance and the luster of abnormalities related to the metabolic syndrome are associated with reduced glomerular filtration rate in patients with type 2 diabetes. Diabetes Care 2006;29:432-434. (Pubitemid 44106535)
8. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140:167-174.
9. Alexander MP, Patel TV, Farag YM et al. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis 2009;53:751-759.
10. Ritz E. Kidney damage in metabolic syndrome: Nip it in the bud. Am J Kidney Dis 2009;53:726-729.
11. Ryu S, Chang Y, Woo HY et al. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am J Kidney Dis 2009;53: 59-69.
12. Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000;58:293-301. (Pubitemid 30429874)
13. Lucove J, Vupputuri S, Heiss G et al. Metabolic syndrome and the development of CKD in American Indians: The Strong Heart Study. Am J Kidney Dis 2008;51:21-28. (Pubitemid 350296515)
14. Ninomiya T, Kiyohara Y, Kubo M et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am J Kidney Dis 2006;48:383-391. (Pubitemid 44247252)
15. Lea J, Cheek D, Thornley-Brown D et al.; AASK Study Investigators. Metabolic syndrome, proteinuria, and risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis 2008;51:732-740.
16. Tomaszewski M, Charchar FJ, Maric C et al. Glomerular hyperfiltration: A new marker of metabolic risk. Kidney Int 2007;71:816-821. (Pubitemid 46624026)
17. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-2140. (Pubitemid 41716445)
18. Rowe JW, Young JB, Minaker KL et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981;30:219-225. (Pubitemid 11026317)
19. Karnib HH, Ziyadeh FN. The cardiorenal syndrome in diabetes mellitus. Diabetes Res Clin Pract 2010;89:201-208.
20. Ceriello A. New insights on oxidative stress and diabetic complications may lead to "causal" antioxidant therapy. Diabetes Care 2003;26:1589-1596. (Pubitemid 36929196)
21. Kitada M, Zhang Z, Mima A et al. Molecular mechanisms of diabetic vascular complications. J Diabetes Invest 2010;1:77-89.
22. Dandona P, Aljada A, Mohanty P et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-3265. (Pubitemid 32674120)
23. Hopps E, Noto D, Caimi G et al. A novel component of the metabolic syndrome: The oxidative stress. Nutr Metab Cardiovasc Dis 2010;20:72-77.
24. Hillege HL, Fidler V, Diercks GF et al.; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-1782.
25. Gerstein HC, Mann JF, Yi Q et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001;286:421-426. (Pubitemid 32681484)
26. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A et al. Metabolic syndrome in Mexican Adults: Results from the National Health and Nutrition Survey 2006. Salud Publica Mex 2010;52:S11-S18.